221 related articles for article (PubMed ID: 37723590)
1. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590
[TBL] [Abstract][Full Text] [Related]
2. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
bioRxiv; 2023 Jan; ():. PubMed ID: 36712023
[TBL] [Abstract][Full Text] [Related]
3. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma.
Mi H; Ho WJ; Yarchoan M; Popel AS
Front Immunol; 2022; 13():892250. PubMed ID: 35634309
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Ho WJ; Zhu Q; Durham J; Popovic A; Xavier S; Leatherman J; Mohan A; Mo G; Zhang S; Gross N; Charmsaz S; Lin D; Quong D; Wilt B; Kamel IR; Weiss M; Philosophe B; Burkhart R; Burns WR; Shubert C; Ejaz A; He J; Deshpande A; Danilova L; Stein-O'Brien G; Sugar EA; Laheru DA; Anders RA; Fertig EJ; Jaffee EM; Yarchoan M
Nat Cancer; 2021 Sep; 2(9):891-903. PubMed ID: 34796337
[TBL] [Abstract][Full Text] [Related]
5. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis.
Qu C; Wu Q; Lu J; Li F
Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188
[TBL] [Abstract][Full Text] [Related]
7. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Yang X; Shi J; Chen X; Jiang Y; Zhao H
Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
[TBL] [Abstract][Full Text] [Related]
9. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
Akkız H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma.
Xie Z; Huang J; Li Y; Zhu Q; Huang X; Chen J; Wei C; Luo S; Yang S; Gao J
Sci Rep; 2023 Nov; 13(1):18799. PubMed ID: 37914817
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
12. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy.
Ho WJ; Sharma G; Zhu Q; Stein-O'Brien G; Durham J; Anders R; Popovic A; Mo G; Kamel I; Weiss M; Jaffee E; Fertig EJ; Yarchoan M
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33219090
[TBL] [Abstract][Full Text] [Related]
13. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
15. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
16. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
17. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment.
Wang YF; Yuan SX; Jiang H; Li ZX; Yin HZ; Tan J; Dai ZH; Ge CM; Sun SH; Yang F
Theranostics; 2022; 12(9):4163-4180. PubMed ID: 35673582
[No Abstract] [Full Text] [Related]
18. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.
Simoes CC; Thung SN; Fiel MI; Sung MW; Schwartz ME; Ward SC
Mod Pathol; 2021 Apr; 34(4):823-833. PubMed ID: 32989224
[TBL] [Abstract][Full Text] [Related]
19. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
20. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
